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Variceal hemorrhage is a common and devastating complication of portal hypertension and is a leading cause of death in patients
with cirrhosis. The management of gastroesophageal varices has evolved over the last decade resulting in improved mortality
and morbidity rates. Regarding the primary prevention of variceal hemorrhaging, nonselective 𝛽-blockers should be the first-
line therapy in all patients with medium to large varices and in patients with small varices associated with high-risk features such
as red wale marks and/or advanced cirrhosis. EVL should be offered in cases of intolerance or side effects to 𝛽-blockers, or for
patients at high-risk for variceal bleeding who have medium or large varices with red wale marks or advanced liver cirrhosis. In
acute bleeding, vasoactive agents should be initiated along with antibiotics followed by EVL or endoscopic sclerotherapy (if EVL is
technically difficult) within the first 12 hours of presentation.Where available, terlipressin is the preferred agent because of its safety
profile and it represents the only drug with a proven efficacy in improving survival. All patients surviving an episode of bleeding
should undergo further prophylaxis to prevent rebleeding with EVL and nonselective 𝛽-blockers.
1. Introduction
Portal hypertension is the main complication of cirrhosis
and the gradient between portal pressure and inferior vena
cava pressure, the hepatic venous pressure gradient (HVPG),
is increased over the normal value of 5mmHg. Clinically
significant portal hypertension is defined as having anHVPG
of 10mmHg ormore. Esophageal varices are present in nearly
30% to 40% of patients with compensated cirrhosis and
in 60% of those with decompensated cirrhosis [1]. Variceal
hemorrhages occur only when there is a clinically signifi-
cant portal hypertension, defined as HVPG> 12mmHg [2].
Variceal hemorrhage is perhaps the most devastating portal
hypertension-related complication in patients with cirrhosis,
occurring in up to 30% of such individuals during the course
of their illness. Moreover, variceal hemorrhage leads to dete-
rioration in liver function and is a common trigger for other
complications of cirrhosis, such as bacterial infections or hep-
atorenal syndrome. The 1-year rate of a first bleeding episode
is 5–15% and its risk is defined by variceal size, red signs on
the varices, and severity of liver disease in patients [3]. As
many as 70% of survivors have recurrent bleeding within 1
year after the index hemorrhage [4]. Althoughmortality rates
of variceal hemorrhage in patients with cirrhosis have been
falling over the last few decades due to the implementation
of effective treatments and improvements in general medical
care, it still carries a mortality rate of up to 20% within 6
weeks of the bleeding episode [5, 6]. Management of patients
with gastroesophageal varices includes: prevention of varices
(preprimary prophylaxis), primary prophylaxis to prevent the
initial bleeding episode, the control of an acute hemorrhage,
and the prevention of recurrent bleeding after a first episode
(secondary prophylaxis).This review summarizes the current
management and prevention of variceal hemorrhage.
2. Prevention of Varices
and Primary Prophylaxis to Prevent
a First Variceal Hemorrhage
Every patient with a new diagnosis of cirrhosis should have
an esophagogastroduodenoscopy to look for the presence
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and size of varices. Nonselective 𝛽-blockers reduce portal
pressure by an average of 15–20%. However, in patients with-
out varices, a large multicenter, placebo-controlled, double-
blinded trial failed to show any benefits of nonselective 𝛽-
blockers (timolol) in the prevention of varices [7]. Serious
adverse events were more common among patients in the
timolol group. Therefore, treatment with nonselective 𝛽-
blockers is not recommended in this setting.
Primary prophylaxis is the prevention of the first variceal
bleeding in patients with varices. The most common means
of primary prophylaxis are either pharmacological or by
endoscopy.
The nonselective 𝛽-blockers have been the most widely
studied medications in randomized controlled trials evalu-
ating the efficacy of primary prophylaxis in patients with
portal hypertension. In patients with low-risk, small varices
(without red wale marks and in the absence of severe
liver disease), there is limited evidence that shows that
their growth may be slowed by the use of nonselective 𝛽-
blockers [8]. Therefore, patients with small varices not using
nonselective 𝛽-blockers, should be considered for endoscopy
every 2 years to evaluate the progression of varices [9].
In patients with small varices that are associated with a
high-risk of hemorrhaging (varices with red wale marks
or varices in a patient with Child-Pugh B or C disease),
nonselective 𝛽-blockers are recommended [3, 10]. In patients
with medium/large varices, a meta-analysis of 11 trials that
included 1,189 patients evaluating nonselective 𝛽-blockers
(ex. propranolol and nadolol) versus no active treatment or
placebo in the prevention of first variceal hemorrhage showed
that 𝛽-blocker reduced the bleeding risk from 30% to 14%
(relative risk reduction of 47%) [11]. The number of patients
that needed to be treated (NNT) with 𝛽-blockers to prevent
one bleeding episode was estimated to be 10. Also, mortality
was reduced with 𝛽-blockers. Once a patient is started on
a 𝛽-blocker to prevent variceal hemorrhage, the treatment
should be lifelong one because the bleeding risk returns to
the baseline if the treatment is withdrawn [12].
The dose of 𝛽-blockers is titrated on the basis of clinical
measurements by incremental increases in dosage to reach
an endpoint resting heart rate of 55 beats per minute, a
reduction of 25% from the baseline rate, or the development
of side effects. The advantages of nonselective 𝛽-blockers
are that their cost is low, expertise is not required for their
use, and they may prevent other complications, such as
bleeding from portal hypertensive gastropathy, ascites, and
spontaneous bacterial peritonitis because they reduce portal
pressure [13, 14]. However, the use of 𝛽-blockers is limited by
their side-effect profile, which includes hypotension, fatigue,
lethargy, depression, and dyspnea in patients with associated
pulmonary disease. Due to concomitant diseases such as
reactive airway disease, congestive heart failure, bradycardia,
and heart block, 15–20% of patients are unable to take 𝛽-
blockers.
Carvedilol, a nonselective 𝛽-blocker with an added
vasodilatory effect through intrinsic 𝛼1-adrenergic activity,
has been shown to produce a greater decrease in portal pres-
sure than propranolol, an effect probably related to an associ-
ated decrease in hepatic and portocollateral resistance [15].
However, the vasodilating effect also causes mild systemic
hypotension, which may be of concern in decompensated
cirrhosis. In a recent randomized, controlled trial, it was
associated with lower rates of first variceal hemorrhage (10%
versus 23%) than endoscopic variceal ligation (EVL) and had
an acceptable side effect profile [16].More data will be needed
on its effectiveness and long-term safety.
The efficacy and safety of losartan and irbesartan,
angiotensin-II-receptor blockers, in lowering portal pressure
has been established in cirrhosis patients [17], but the risk
of systemic hypotension and renal failure precludes their use
in patients with decompensated cirrhosis [18, 19]. Currently,
angiotensin-II-receptor blockers are not recommended in the
setting of portal hypertension.
Endoscopic therapy is another mean of primary pro-
phylaxis. The success of endoscopic sclerotherapy in the
treatment of acute variceal bleeding led to the extensive
evaluation of sclerotherapy for the prevention of the first
variceal bleeding. While early studies showed promising
results [20, 21], subsequent larger trials showed no benefit
[22, 23], and a prospective, randomized trial was terminated
prematurely because of an increased mortality rate in the
endoscopic sclerotherapy group [24]. Based on this data,
endoscopic sclerotherapy is not recommended for primary
prophylaxis.
In recent years, EVL has replaced endoscopic scle-
rotherapy. In patients with medium or large varices, either
nonselective 𝛽-blockers or EVL can be used, since a meta-
analysis of high-quality, randomized, controlled trials has
shown equivalent efficacy and no differences in survival [25].
However, EVL should be preferred for patients at high-risk
for variceal bleeding who have medium or large varices with
red wale marks or advanced liver cirrhosis. Combination
therapy with nonselective 𝛽-blockers and EVL does not
seem to confer any additional benefit because addition of 𝛽-
blockers does not decrease the probability of first bleed or
death in patients on EVL, but increased the side effects [26].
3. The Management of Acute Hemorrhage
The rate of death from acute variceal hemorrhage has been
decreasing over the past two decades, probably as a result
of improved general management (with short-term antibi-
otic prophylaxis) and more effective therapies (EVL and
vasoactive drugs) [27]. The management of acute variceal
hemorrhage consists of general care, such as adequate fluid
resuscitation, airway protection, and prophylactic antibiotics,
and specific therapy, such as vasoactive drugs, endoscopic
treatment, or surgical or radiological shunts.
The basic medical principles of airway, breathing and
circulation are followed to achieve hemodynamic stability.
Airway protection should be provided, especially in patients
with hepatic encephalopathy, since the patient is at risk for
bronchial aspiration of gastric contents and blood. Tracheal
intubation is mandatory if there is any concern about the
safety of the airway. Blood volume replacement should be
initiated as soon as possible with plasma expanders, aiming
at maintaining a systolic blood pressure of approximately
100mmHg. Avoiding prolonged hypotension is particularly
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important to prevent infection and renal failure, which are
associated with increased risk for rebleeding and death [28].
Packed red blood cells are transfused conservatively to keep
the target hemoglobin level between 7 and 8 g/dl, as excessive
blood volume replacement can increase portal pressure and
the risk of rebleeding [6, 29]. Fresh frozen plasma and
platelets, although frequently used, do not reliably correct
coagulopathy and can induce volume overload [30].
Cirrhosis is frequently associated with defects in both
humoral and cellular host defense, hence increasing the risk
for infection. The most frequent infections are spontaneous
bacterial peritonitis (50%), urinary tract infections (25%),
and pneumonia (25%) [31]. Two meta-analyses have shown
that prophylactic antibiotics in patients with acute variceal
hemorrhage prevent infection and significantly increase the
short-term survival rate [32, 33]. Therefore, antibiotic pro-
phylaxis is an essential part of therapy for patients with
cirrhosis presenting with upper gastrointestinal bleeding
and should be instituted from admission. Antibiotic pro-
phylaxis with ceftriaxone (1 g/day for 7 days) is recom-
mended in patients with severe liver disease, high prevalence
of quinolone resistance, or prior quinolone prophylaxis,
whereas others can receive oral norfloxacin [34, 35].
In suspected variceal hemorrhages, vasoactive drugs
need to be started as soon as possible, prior to diagnostic
endoscopy. Vasoactive therapy should be maintained for up
to 5 days depending on control of bleeding and severity of
liver disease. They improve the control of variceal hemor-
rhage when combined with endoscopic therapy and when
compared to endoscopic therapy alone [36]. Vasoactive treat-
ment aims at controlling the bleeding episode by lowering
the portal pressure and decreasing variceal blood flow. Two
types of vasoactive drugs that are used currently in the man-
agement of acute variceal bleeding are present: vasopressin
and its analogs (terlipressin) and somatostatin and its analogs
(octreotide/vapreotide). In practice, the choice of drugs is
usually based on availability and cost.
Vasopressin, which is a powerful vasoconstrictor, low-
ers portal pressure but also causes systemic vasoconstric-
tion. But, its use is limited by multiple side-effects related
to splanchnic vasoconstriction (e.g., bowel ischemia) and
systemic vasoconstriction (e.g., hypertension, myocardial
ischemia). Terlipressin is a synthetic vasopressin analog with
a prolonged half-life and possessing far fewer side effects.
Side effects may include transient abdominal pain as well
as self-limited diarrhea. There was a statistically significant
reduction in failure to control bleeding with terlipressin
compared with placebo. More importantly, terlipressin is the
only pharmacologic agent that significantly reducesmortality
compared with placebo [37]. Somatostatin has been used
in the pharmacological treatment of variceal hemorrhaging
because it leads to splanchnic vasoconstriction and decreases
portal pressure without the adverse effects of vasopressin on
the systemic circulation. Some side effects such as nausea,
vomiting, and hyperglycemia may occur in up to one-
third of patients. Several randomized controlled studies have
shown its efficacy in controlling bleeding [38–40]. However,
somatostatin did not reduce mortality [11]. Octreotide and
vapreotide are cyclic synthetic somatostatin analogs with
longer half-lives than native somatostatin. Octreotide is
safe and few major side effects are reported. The efficacy
of octreotide as a single therapy for variceal bleeding is
controversial, because two studies using octreotide or placebo
after the control of the initial bleeding episode failed to
show any difference in early rebleeding or mortality between
the two treatment groups [41, 42]. Tachyphylaxis is another
limitation [43]. However, octreotide appears to be useful as
an adjunct to endoscopic therapy (endoscopic sclerotherapy
or EVL) to achieve hemostasis [36].
The current management cornerstone of variceal hemor-
rhage is endoscopic treatment. Endoscopic therapy is capable
of stopping bleeding in nearly 90% of patients. Endoscopy
should be performed as soon as possible and not more than
12 hours after presentation. The two endoscopic methods
available are sclerotherapy and variceal ligation. Endoscopic
sclerotherapy arrests hemorrhage in 80% to 90% of patients
and decreases the risk for early rebleeding, although an
improvement in patient survival has never been shown
[11]. EVL is a relatively newer therapeutic modality and
has replaced endoscopic sclerotherapy as the endoscopic
procedure of choice due tomore effective control of bleeding,
obliteration of varices in fewer treatment sessions, a lower
rebleeding rate, and lower mortality [44]. Therefore, by
consensus, EVL is the preferred form of endoscopic therapy
[3, 10]. However, endoscopic sclerotherapy is an option when
EVL is not available or technically difficult.
Despite urgent endoscopic and/or pharmacologic ther-
apy, variceal hemorrhages cannot be controlled or recured in
about 10% to 20% of patients. In this case the patient should
be offered an additional treatment before the patient’s clinical
status deteriorates. Transjugular intrahepatic portosystemic
shunt (TIPS) has clinical efficacy as salvage therapy in
whom standard combination therapy with endoscopic and
pharmacological therapy fails, but the mortality rate is high
(30–50%) because these patients usually have deteriorated
liver function [23, 45, 46]. Both TIPS and surgical shunts are
extremely effective in controlling variceal bleeding (control
rate approaches 95%) but due to the efficacy, simplicity, and
a better cost-effectiveness ratio of TIPS, surgical shunts have
been practically abandoned [47].
The high mortality associated with the use of TIPS as a
rescue treatment raises the question of whether patients with
poor prognostic indicatorsmight benefit from amore aggres-
sive therapeutic approach. Two randomized, controlled trials
have shown that an early placement of such a shunt (within up
to 72 hours after admission) was associated with a reduction
in failure to control bleeding, lower incidence of rebleeding,
and a decreased mortality rate among high-risk patients
(Child-Pugh C or an HVPG of >20mmHg) [48, 49]. In
addition, the TIPS group did not have an increased incidence
of hepatic encephalopathy. Therefore, the early use of TIPS
could be considered in these patients.
The use of a Sengstaken-Blakemore or Minnesota tube
can be a life-savingmaneuver ifmedical and endoscopicmea-
sures fail to arrest the hemorrhage. Pneumatic compression
of the fundus and the lower esophagus stops bleeding in
approximately 85% of cases. Bleeding recurs after deflation
in over half of the cases within 48 hours of placement and
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major complications including aspiration pneumonia and
esophageal perforation may occur in up to 20% to 30%
of patients. Balloon tamponade is only used as a tempo-
rary measure (inflated for 12 h or less) to control bleeding
while a definitive therapy (TIPS or endoscopic therapy) is
planned.
4. Prevention of Recurrent Variceal
Hemorrhage (Secondary Prophylaxis)
Patients surviving in the first episode of variceal hemorrhages
are at high-risk of recurrent bleeding, with a mortality of
33%, and thus should have secondary therapy to prevent
further variceal bleeding [11]. The main means of secondary
prophylaxis are pharmacological, by endoscopic treatment or
a combination, or the use of shunts, usually a TIPS.
All patients who are deemed compliant and have no
contraindications should be considered for pharmacologic
therapy. Nonselective 𝛽-blockers significantly decreased the
risk of rebleeding and mortality [50]. Endoscopic sclerother-
apy does significantly decrease rebleeding rates andmortality,
but it has been associated with serious complications, the
most common of which are esophageal stricture and bleeding
from treatment-induced ulcers [51]. Endoscopic sclerother-
apy has been replaced by EVL, since it has significantly
better outcomes (regarding rebleeding, lower mortality, and
complication) compared with sclerotherapy [11, 52]. The
results of randomized, controlled trials comparing variceal
ligation with 𝛽-blockers (nadolol) showed that combination
treatment gives the lowest rebleeding rates, but without
differences in survival [53]. The combination therapy of EVL
and nonselective 𝛽-blockers for the prevention of recurrent
variceal hemorrhaging is now the preferred therapy [6].
Patients who are intolerant or have contraindications to
pharmacological therapy should receive EVL alone.
Finally, TIPS in secondary prophylaxis has been shown to
lower rebleeding rates when compared to the endoscopic and
pharmacologic therapy [54]. However, no mortality benefit
has been demonstrated with TIPS and its use is associated
with higher costs and incidence of hepatic encephalopathy.
Therefore, the use of TIPS in secondary prophylaxis is not
recommended. However, TIPS or surgical shunt should be
considered in patients with Child-Pugh A or B who expe-
rience recurrent variceal hemorrhaging despite combined
treatment with EVL and nonselective 𝛽-blockers [55]. Liver
transplantation should be considered for patients who meet
indications for liver transplantation.
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